Moneycontrol PRO
UPCOMING EVENT:Attend Traders Carnival Live. 3 days 12 sessions at Rs.1599/-, exclusive for Moneycontrol Pro subscribers. Register now!
you are here: HomeNewsBusiness

AstraZeneca Pharma India gets DCGI nod to import, market Selumetinib capsules

The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing.

September 27, 2021 / 08:22 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm AstraZeneca Pharma India said it has received import and market permission from the Indian drug regulator for Selumetinib capsules.

The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing.

The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added.

Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.
PTI
first published: Sep 27, 2021 08:24 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark